论文部分内容阅读
Efficacy, safety and predictive biomarker results from a randomized phase Ⅱ study comparing MPDL3280
【作 者】
：
【机 构】
：
Virginia Cancer Specialists Research Institute, US Oncology Research, Fairfax, VA
【出 处】
：
2015年临床肿瘤学新进展学术研讨会
【发表日期】
：
2015年3期
其他文献
会议
Phase Ⅲ trial of etirinotecan pegol (EP) versus Treatment of Physician’s Choice (TPC) in patients (p
会议
会议
Results from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advance
会议
Relationship of omission of adjuvant radiotherapy to outcomes of locoregional control and disease-fr
会议
A multi-center randomized controlled trial of mFOLFOX6 with or without radiation in neoadjuvant trea
会议
Radiofrequency ablation (RFA) combined with chemotherapy for unresectable colorectal liver metastase
会议
Efficacy of rociletinib (CO-1686) in plasma-genotyped T790M-positive non-small cell lung cancer (NSC
会议
会议